학술논문
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
Document Type
Article
Author
Turner, N.C. ; Alarcón, E.; Armstrong, A.C.; Philco, M.; López Chuken, Y.A.; Sablin, M.-P.; Tamura, K.; Gómez Villanueva, A.; Pérez-Fidalgo, J.A.; Cheung, S.Y.A. ; Corcoran, C.; Cullberg, M.; Davies, B.R.; de Bruin, E.C.; Foxley, A.; Lindemann, J.P.O.; Maudsley, R.; Moschetta, M.; Outhwaite, E.; Pass, M.; Rugman, P.; Schiavon, G.; Oliveira, M.
Source
In Annals of Oncology May 2019 30(5):774-780
Subject
Language
ISSN
0923-7534